Augmentation by Interleukins of the Antibody Response to a Conjugate Vaccine against Haemophilus influenzae B

  • Garvin S. BixlerJr.
  • Subramonia Pillai
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 303)


Interleukins have been recognized as potential adjuvants for use during vaccination. The immunogenicity of some poorly immunogenic bacterial capsular polysaccharides have been improved by conjugation to a protein carrier. Augmentation of the immune response to these glycoconjugates, however, may be realized in the presence of interleukins. The antibody response to one such vaccine which comprises a oligosaccharide derived from the capsule of Haemophilus influenzae type b coupled to CRM197 (HbOC) can be augmented in this manner. A suboptimal dose (0.1 μg) of HbOC and varying concentrations of IL−1α or IL−1β (102 − 5 × 105 U) were injected intramuscularly at 0 and 2 weeks into Swiss Webster mice. Vaccines were also formulated with and without aluminum phosphate. Antibody to the oligosaccharide was determined by Farr assay. In 3/3 experiments, IL−1α enhanced primary and secondary antibody responses whereas with IL−lβ, only a slight increase in the primary antibody response was seen but enhanced secondary responses were observed. Thus, IL-la and to some extent,IL−1β enhanced the primary and secondary antibody responses to a glycoconjugate vaccine.


Antibody Response Haemophilus Influenzae Conjugate Vaccine Immature Host Primary Immunization 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Anderson, P. W. and Eby, R.J., 1987, European Patent 0-245-045-A2, Praxis Biologics, Inc.Google Scholar
  2. Anderson, P. W. and Eby, R. J., 1990, U. S. Patent 4,902,506, University of Rochester.Google Scholar
  3. Anderson, P., Peter, G, Johnston, R. B. J., Wetterlow, L.H., and Smith, D. H., 1972, Immunization of humans with polyribophsophate, the capsular antigen of Hemophilus influenzae type b, J. Clin. Invest., 51:39.PubMedCrossRefGoogle Scholar
  4. Anderson, P., Pichichero, M., and Insel, R..,1985, Immunogens consisting of oligosaccharides from the capsule of Haemophilus influenzae type b coupled to diphtheria toxoid or the toxin protein CRM197, J. Clin. Invest., 76:52.PubMedCrossRefGoogle Scholar
  5. Booth, R. J., Prestige, R. L., and Waston, J. D., 1983, Constitutive production by the WEHI-3 cell line of a B cell growth and differentiation factor that co-purifies with interleukin 1, J. Immunol., 131:577.Google Scholar
  6. Dinarello, CA., 1988, Biology of interleukin 1, FASEB J., 2:108.PubMedGoogle Scholar
  7. Eby, R. J., Madore, D., Johnson, C., Smith, D.H., Connelly, B., McHenry, C. L., and Meyers, M., 1986, A new stable vaccine for Haemophilus influenzae b highly immunogenic for human infants composed of oligosaccharides of capsular polymer (PRP) linked to CRM197, Pediatr. Res., 20:308A.Google Scholar
  8. Farr, R.S., 1958, A quantitative immunochemical measure of the primary interaction between I*BSA and antibody, J. Infect. Dis., 103:239.PubMedCrossRefGoogle Scholar
  9. Hoffman, M. K., 1979, Control of B cell differentiation by macrophages, Ann. N. Y. Acad. Sci., 322:577.Google Scholar
  10. Hoffman, M.K., Gilbert, K.M., Hirst, J. A., and Scheid, M., 1987, An essential role for interleukin 1 and a dual function for interleukin 2 in the immune response of murine B lymphocytes to sheep erythrocytes, J. Mol. Cell. Immunol., 3:29.Google Scholar
  11. Insel, R.A., and Anderson, P.W., 1986, Oligosaccharide-protein conjugate vaccines induce and prime for oligoclonal IgG antibody responses to the Haemophilus influenzae b capsular polysaccharide in human infants, J. Exp. Med., 163:262.PubMedCrossRefGoogle Scholar
  12. Madore, D. V., Johnson, C. L., Phipps, D. C., Popejoy, L. A., Eby, R., and Smith, D. H., 1990a, Safety and immunologic response to Haemophilus U type b oligosaccharide-CRM197 conjugate vaccine in 1–to 6-month-old infants, Pediatrics, 85:331.PubMedGoogle Scholar
  13. Madore, D. V., Johnson, C. L., Phipps, D. C., Meyers, M. G., Eby, R., and Smith, D. H., 1990b, Safety and immunogenicity of Haemophilus influenzae type b oligosaccharide-CRM197 conjugate vaccine in infants aged 15 to 23 months, Pediatrics, 86:527.PubMedGoogle Scholar
  14. March, C. J., Mosley, B., Larsen, A., Cerretti, P., Braedt, G., Price, V., Gillis, S., Henny, C.S., Kronheim, S.R., Grabstein, K., Conlon, P. J., Hopp, T. P., and Cosman, D., 1985, Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs, Nature, 315:641.PubMedCrossRefGoogle Scholar
  15. Mizel, S. B., and Ben-Zui, A., 1980, Studies on the role of LAF (interleukin 1) in antigen induced lymph node lymphocyte proliferation, Cell, Immunol., 54:382.CrossRefGoogle Scholar
  16. Nencioni, L., Villa, L., Tagliabue, A., Antoni, G., Presentini, F., Perin, R., Siverstri S., and Bonaschi, D., 1987, In vivo immunostimulating activity of the 163-171peptide of human IL−1α. J. Immunol., 139:800.PubMedGoogle Scholar
  17. Reed, S.G., Pihl, D. L., Conlon, P.J., and Grabstein K. H., 1989, IL-1 as adjuvant. Role of T cells in the augmentation of specific antibody production by recombinant human IL−1α, J. Immunol., 142:3129.PubMedGoogle Scholar
  18. Rosenwasser, L.J., and Dinarello, C. A., 1981, Ability of human leukocytic pyrogen to enhance phytohemagglutinin induced murine thymocyte proliferation, Cell. Immunol., 63:134.PubMedCrossRefGoogle Scholar
  19. Schnader, J. W., 1973, Mechanism of activation of the bone-marrow-derived lymphocyte. III. A distinction between a macrophage-produced triggering signal and the amplifying effect on trigger B lymphocytes of allogeneic interactions, J. Exp. Med., 138:1446.Google Scholar
  20. Staruch, M. J., and Wood, D.D., 1983, The adjuvanticity of interleukin 1 in vivo, J. Immunol., 130:2191.PubMedGoogle Scholar
  21. Wood, D. D., 1979, Mechanism of action of human B cell-activating factor. I. Comparison of plaque-stimulating activity with thymocyte-stimulating activity, J. Immunol., 123:2400.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • Garvin S. BixlerJr.
    • 1
  • Subramonia Pillai
    • 1
  1. 1.Praxis Biologics, Inc.RochesterUSA

Personalised recommendations